Welcome to the EduCationaL I-O Patient CaSE Meeting (ECLIPSE) program. The ECLIPSE program is a series of live educational peer-to-peer webinars that are also recorded and available for on demand viewing.
To EDUCATE lung cancer treaters to expand their knowledge on the use of the dual immunotherapy nivolumab + ipilimumab in cancer patients based on patient case presentations in an international live virtual pan-tumor ‘meet the expert’ setting.
The program began in 2021 with three educationally stimulating and highly engaging webinars targeting pulmonologists who treat patients with metastatic non-small cell lung cancer (mNSCLC) and unresectable malignant pleural mesothelioma (uMPM). For each webinar 2-3 medical experts from various oncological disciplines discuss immunotherapy and share their experiences of managing their patients with these medicines.
Sjaak Burgers - Dual I-O: Experience in Mesothelioma
Prof. dr. Solange Peters - Dual I-O: Experience in NSCLC
Efficacy parameters, management of syndrome of inappropriate antidiuretic hormone and adrenal insufficiency, management of rash grade 1–2, second-line treatment options in mNSCLC, rechallenge with immunotherapy for patients with mNSCLC and mesothelioma who experience a relapse on immunotherapy, management of patients with brain metastases, treatment discontinuations and immune-mediated adverse events and how their rates compare with nivo + ipi regimens in other licensed tumors and quality of life.
Prof. dr. Arnaud Scherpereel - Dual I-O: Experience in Mesothelioma
Prof. dr. Martin Reck - Dual I-O: Experience in NSCLC
Efficacy parameters, pulmonary immune related adverse events, management of hyperthyreosis, integrating the patient in treatment decision making, maintaining normality for patients whilst receiving treatment, patient selection for dual immunotherapy regimens, communicating to the patient on treatment options and rationale for treatment selection as well as rationale for discontinuation of immunotherapy, management of immune-mediated adverse reactions, rechallenging and treatment sequencing.
Dr. Toby Talbot - Dual I-O: Experience in Mesothelioma
Prof. dr. Helena Linardou - Dual I-O: Experience in NSCLC
Management of immune related hepatitis, efficacy parameters in both lung and brain, as well as management of hypophysitis, rationale and patient selection for dual immunotherapy vs monotherapy in NSCLC, duration of treatment and stopping after two years in NSCLC & mesothelioma, strategies for discontinuing treatment due to toxicities, rechallenging in NSCLC, second-line treatment options, and patient education with regards to toxicities.
Prof. Dr. Paul Baas - Dual I-O: Experience in Mesothelioma
Prof. Dr. Luis Paz- Ares - Dual I-O: Experience in NSCLC
Efficacy parameters, management of hepatotoxicity, nephritis and diarrhea, rationale for treatment regimen in CM-743, quality of life on particular arms in CM-743 for patients with mesothelioma, treatment discontinuation after toxicities as well as re-challenge, managing patients with brain metastases and use of immunosuppressants with immunotherapy for toxicity management
Prof. dr. Pierre Coulie – MOA Dual IO
Prof. dr. J. Larkin - Dual I-O: Experience in Renal Cell Carcinoma
Dr. I. Demedts - Dual I-O: Experience in NSCLC
Rationale for adding chemotherapy to dual I-O as well as the type of chemotherapy, mechanism behind ipilimumab toxicities and the dose-dependent relationship key properties of T cells for cancer therapy, the role of CTLA-4 and PD-1 checkpoints on T cells, treatment duration, proposed mechanisms for irAEs, management of uveitis, polyarthralgia, diarrhea, skin toxicities, as well as efficacy parameters and key recommendations for pulmonologists who are new to ipilimumab.
Prof. Dr. Benoit Beuselinck - Dual I-O: Experience in Renal Cell Carcinoma
Dr. Mariette Labots - Dual I-O: Experience in Melanoma
Prof. Dr. Jaafar Bennouna - Dual I-O: Experience in NSCLC
Management of fatigue & adrenalitis, brain metastases, management of diarrhea & balanitis, efficacy parameters and safety outcomes